# Patient Characteristics and Elranatamab administration patterns of Real-World Patients Receiving Elranatamab

**First published:** 05/05/2026

**Last updated:** 22/07/2026

Study Planned

## Administrative details

**EU PAS number**

EUPAS1000000853

**Study ID**

1000000853

**DARWIN EU® study**

No

**Study countries**

United States

**Study status**

Planned

# Contact details

**Study institution contact**

Makiko Fukaya makiko.fukaya@pfizer.com

**Study contact**

makiko.fukaya@pfizer.com

**Primary lead investigator**

Chen Yong

**Primary lead investigator**

# Study timelines

**Date when funding contract was signed**

Planned: 31/07/2025

Actual: 31/07/2025

---

**Study start date**

Planned: 27/03/2026

---

**Date of final study report**

Planned: 01/04/2027

# Study protocol

C1071052_PROTOCOL v1.0_16FEB2026_Redacted.pdf (2.31 MB)

# Regulatory

**Was the study required by a regulatory body?**

No

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

# Methodological aspects

## Study type

## Study type list

**Study type:**

Non-interventional study

# Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Use of a Common Data Model (CDM)

**CDM mapping**

No

# Data quality specifications

**Check conformance**

No

**Check completeness**

No

**Check stability**

No

**Check logical consistency**

No

# Data characterisation

**Data characterisation conducted**

No